Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 11, 2006

TechnoVax Licenses Wyeth's Virus-Like Particle Vaccine Technology

  • TechnoVax gained the rights to Wyeth’s patent application in the field of virus-like particle (VLP) technology. This application is based on research conducted by TechnoVax founder, Jose M. Galarza, Ph.D., while serving as principal scientist at Wyeth.

    Technovax explains that the VLP vaccine technology allows for the creation of structures that are morphologically identical to a virus. However, they are unable to replicate or infect cells because they lack the genetic material that is needed. VLP-based vaccines, hence, do not require chemical inactivation or attenuation.

    The patent application covers the preparation of vaccines against a number of potential pandemic organisms. The technology allows for the production of vaccines against influenza in a cell-based rather than an egg-based system. It can also be used for the production of vaccines directed against other infectious agents and cancer targets.

    The agreement provides for an upfront payment, annual minimum royalty payments, milestone payments related to certain development events, royalties on product sales, and an equity grant when TechnoVax completes an initial equity financing.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »